Litcius/Paper detail

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

Benjamin A. Fisher, Antónia Szántó, Wan‐Fai Ng, Michele Bombardieri, Maximilian Posch, Athena Papas, Arwa M. Farag, Thomas Daikeler, Bettina Bannert, Diego Kyburz, Alan Kivitz, Steven E. Carsons, David Isenberg, Francesca Barone, Simon Bowman, Pascal Espié, David Floch, Cyrielle Dupuy, Xiaohui Ren, P. Faerber, A. Wright, Hans Hockey, Michael Rotte, Julie Milojevic, Alexandre Avraméas, Marie‐Anne Valentin, James S. Rush, P Gergely

2020The Lancet Rheumatology126 citationsDOI

Topics & Concepts

MedicinePlaceboTolerabilityInternal medicineCohortClinical endpointInterim analysisGastroenterologyAdverse effectClinical trialSurgeryPathologyAlternative medicineSalivary Gland Disorders and FunctionsDiabetes and associated disordersOcular Surface and Contact Lens